These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Prospective study of a phenformin-like substance (moroxydine chloride) in patients with deficient vessel wall fibrinolysis. Author: Tengborn L, Hedner U, Nilsson IM. Journal: J Med; 1982; 13(5-6):353-64. PubMed ID: 6963328. Abstract: It is known that ethylestrenol and/or phenformin can normalize deficient fibrinolysis in the vessel walls and prevent recurrent thromboembolism (Hedner et al., 1976; Nilsson et al., 1975, 1981). Because of the side-effects of phenformin, we studied the effect of a phenformin-like substance: moroxydine chloride (Kabi 1886), which unlike phenformin, does not cause lactic acidosis. A prospective randomized clinical trial was carried out on 49 patients with a decreased release capacity of fibrinolytic activity (venous occlusion test for 20 min as described by Robertson et al. (1972) on at least two occasions. They received either moroxydine chloride in a dose of 0.04 g/kg a day or no specific treatment. Most of the patients had earlier at least one episode of deep venous thrombosis. At review 6 months after entering the trial, it was found that out of 26 patients receiving moroxydine chloride, the release capacity was normal in 16 (62%), compared with 5 (22%) of the 23 controls. Dicoumarol alone did not seem to have any effect on the fibrinolysis. The only side-effects were occasional diarrhea in two, which was controlled by reduction of the dose, and itching requiring withdrawal of the drug in one. Moroxydine chloride, thus, seems to normalize a defective release capacity of vessel wall in a fair percentage of cases.[Abstract] [Full Text] [Related] [New Search]